Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of its allogeneic cell therapy product, ALLOB®. Interim results are expected in 3Q17.
Sources: Bone Therapeutics; ORTHOWORLD Inc.
Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics...
Bone Therapeutics received notice that the European Patent Office (EPO) will grant the company a patent covering its allogeneic cell therapy technology.
Patents for the technology have been granted in Japan, Australia and Singapore and applications are pending in the U.S., Canada, India and South Korea.
In March, Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of its allogeneic cell therapy product, ALLOB®. Interim results are expected in 3Q17.
Sources: Bone Therapeutics; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.